MorphoSys licenses HuCal Gold technology to Schering-Plough

New York, May 17 - MorphoSys AG said it signed a two-year license agreement for Schering-Plough Corp. to use its HuCal Gold technology in the research and development of human therapeutic antibodies.

Under the agreement, Schering-Plough will be able to use MorphoSys' proprietary antibody library in its drug discovery programs at its research site at Palo Alto, Calif.

Schering-Plough will have the option to develop HuCal-derived therapeutic antibodies against up to 10 disease-related targets.

MorphoSys will receive an upfront payment, annual fees and optional research and development funding.

For therapeutic antibody projects undertaken by Schering-Plough, MorphoSys is eligible to receive license and milestone payments.

Further financial details were not disclosed.

Schering-Plough has an option to extend for three years.

Based in Munich, MorphoSys develops synthetic antibodies used to accelerate drug discovery and target characterization.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.